Please login to the form below

Not currently logged in
Email:
Password:

ovarian cancer

This page shows the latest ovarian cancer news and features for those working in and with pharma, biotech and healthcare.

ViiV’s two-drug HIV combo backed by CHMP

ViiV’s two-drug HIV combo backed by CHMP

CHMP meeting round-up. Among other highlights the CHMP backed two biosimilar medicines - Amgen’s Kanjinti version of Roche’s Herceptin (trastuzumab) for the treatment of breast and gastric cancer and ... It also gave its blessing to Clovis

Latest news

  • FDA approves another home genetic testing service FDA approves another home genetic testing service

    breast and ovarian cancer. ... certain individuals who may be at increased breast, ovarian or prostate cancer risk and who might not otherwise get genetic screening, and is a step forward in the availability of DTC

  • CHMP backs AZ’s Lynparza for ovarian cancer maintenance CHMP backs AZ’s Lynparza for ovarian cancer maintenance

    CHMP backs AZ’ s Lynparza for ovarian cancer maintenance. Studies show that the drug reduced risk of disease progression. ... Zejula was approved for ovarian cancer maintenance last year, while Rubraca is also in late-stage development for this

  • Pfizer’s leukaemia drug Mylotarg backed for use in EU Pfizer’s leukaemia drug Mylotarg backed for use in EU

    sunitinib) to include it use to prevent the return of kidney cancer in patients who have had surgery and are at high risk of their cancer coming back. ... The CHMP also gave positive opinions to: a new maintenance indication for AstraZeneca and Merck

  • AZ expects return to growth this year after 2017 decline AZ expects return to growth this year after 2017 decline

    PARP inhibitor Lynparza for ovarian cancer weathered competition from other drugs in the class and grew by a third to $297m in the year, thanks in part to the assistance of ... MSD which is helping to commercialise the drug and a new indication in breast

  • AZ and Merck & Co get FDA breast cancer nod for Lynparza AZ and Merck & Co get FDA breast cancer nod for Lynparza

    AstraZeneca and Merck &Co have been awarded FDA approval for Lynparza in BRCA-positive advanced breast cancer - the first drug in the PARP inhibitor class to be approved outside ovarian cancer. ... Approval beyond ovarian cancer is a big hurdle cleared

More from news
Approximately 31 fully matching, plus 136 partially matching documents found.

Latest Intelligence

  • The tipping point The tipping point

    In 2016 alone, there were approximately 30 oncology drugs in late stage development for breast cancer, leukaemia, lung cancer and ovarian cancer.

  • AI’s potential in the pharma life cycle AI’s potential in the pharma life cycle

    Proactive intervention. Already AI is being used to identify women whose Twitter posts indicate they may have increased risk of developing two relatively rare diseases: ovarian cancer and cervical cancer.

  • Europe vs the US: New drug product approvals Europe vs the US: New drug product approvals

    Among the noteworthy approvals are Lartruvo (for the treatment of soft tissue sarcoma, approved in the EU and US), Rubraca (for the treatment of ovarian cancer, only approved in the US),

  • Deal Watch May 2016 Deal Watch May 2016

    Prima has partnered its immuno-oncology CVac in ovarian cancer by transferring its CVac related assets, including manufacturing protocols, clinical data, patents and know‐ how plus certain assets e.g. ... 110. CSPC Pharmaceutical/ Watson [Allergan].

  • Deal Watch April 2016 Deal Watch April 2016

    The explanation for this is that Janssen are getting rights only for prostate cancer, not ovarian and breast cancer where the product is in phase III and the rights do not ... 500. Tesaro (US). Janssen (US). License and collaboration. Niraparib PARP

More from intelligence
Approximately 0 fully matching, plus 11 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 4 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
CMR

Specialising in medical device market research, our approach is people-centric and we thrive on making connections with clients and research...

Latest intelligence

Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...

Infographics